Analysts question direction as MAP charts narrow migraine co-promo with Allergan
This article was originally published in Scrip
Executive Summary
Allergan and MAP Pharmaceuticals have signed a co-promotion deal for MAP's investigational, inhaled migraine drug Levadex, whereby Allergan has agreed to pay MAP up to $157 million to access MAP's product, where the companies would jointly promote to US specialists upon FDA approval.